Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- (-) Accountable Care Organizations
- Alternative Payment Models
- Biopharmaceutical Innovation
- Bundled Payments
- Clinical Pathways
- Decision Frameworks
- (-) Elements of Value
- Evidence for Decision Making
- (-) Formulary/Benefit Design
- Formulary Development
- Good Practices for Evidence
- Health Care Quality Measures
- Health Spending
- Health Spend Management
- (-) High-Deductible Health Plans
- Impact on Outcome & Spending
- Individual Treatment Effects & Personalized Access
- IRA Implementation
- Low-Value Care
- Pandemic Response
- Patient Cost Sharing
- Paying for Cures
- Policy & Regulatory Barriers
- Real-World Data
- Real-World Evidence
- Regulatory Barriers & Challenges
- Understanding Health Spending
- Utilization Management & Step Therapy
- (-) Value-Based Contracts
- Value-Based Insurance Design
- Value Assessment
- Value Assessment Frameworks
- Value Assessment Methods
Resource Type
Display Only
Showing 119 Results
Study of U.S. Commercial Health Plans Shows Widespread Variation in Coverage and Reimbursement for Specialty Medicines
Research published in Health Affairs shows that insurance coverage and reimbursement for specialty medications varies substantially, finding that only 15.9% of drug coverage policies were consistent…
Financial Impact of HSA-HDHP Reform to Improve Access to Chronic Disease Management Medications
According to an issue brief from VBID Health, providing pre-deductible coverage for medicines used to treat common chronic conditions could lower out-of-pocket costs and increase medication adherence…
Regulatory Barriers Impair Alignment of Biopharmaceutical Price and Value
This white paper highlights the challenges biopharmaceutical manufacturers and payers face when developing value-based contracts.
Managing PBMs: An Employer’s Perspective
During a webinar hosted by the Integrated Benefits Institute on March 5, Chuck Reynolds, consultant for Benfield, a Division of Gallagher Benefit Services, and Kristen Putnam, Director, Global…
A Comparison of Coverage Restrictions for Biopharmaceuticals and Medical Procedures
Payer evaluation and coverage of pharmaceuticals and medical procedures may differ independent of their clinical benefit. Therapy access depends on factor other than cost and clinical benefit,…
Coverage Decisions May Drive Potential Health Care System Inefficiency
New research from Tufts Medical Center and the National Pharmaceutical Council indicates that patient access to therapies depends on factors other than cost and clinical benefit.
NPC in Chain Drug Review: Pharmacy Outlook 2018
NPC President Dan Leonard explores value- and outcomes-based contracts, innovative benefit design, value assessment frameworks and more in his latest commentary for Chain Drug Review.
NPC in AJPB: Working Toward Better Value in Prescription Drug Benefits Management
U.S. employers provide a vital link to health care, with more than 56 percent of them offering health insurance for their employees. However, how employers design those health benefits can vary…
Toward Better Value
There is a disconnect between the important role employers believe their pharmacy benefit managers (PBMs) play in helping to manage prescription drug benefits and employers’ perceptions of the…
NPC Talks Value, Benefit Design at AMCP Research Symposium and Nexus 2017
The National Pharmaceutical Council (NPC) is pleased to be participating in next week’s Academy of Managed Care Pharmacy (AMCP) Nexus 2017 meeting in Dallas, Texas. As a sponsor of and participant in…
NPC in Chain Drug Review: Should Patients With the Same Condition Bear Different Costs?
NPC President Dan Leonard tackles variable copays in his latest commentary for Chain Drug Review. In it, he considers when variable cost-sharing is less acceptable for patients who require higher…
Checking In With Schaeffer-NPC Postdoctoral Fellow in Health Policy, Dr. Ilene Hollin
Ilene Hollin, PhD, is entering the second year of her NPC-USC Schaeffer Center Health Policy fellowship, a post-doctoral, two-year fellowship that seeks to bridge the gap between health research and…
Same Condition, Different Costs: Should Patients Pay Different Amounts?
Patients who have the same condition sometimes pay different out-of-pocket costs for their medications, but when is this differential more appropriate? Join NPC in tackling this dilemma in the…
Opportunities and Challenges With Value-Based Contracting
In his commentary for the American Journal of Pharmacy Benefits, NPC President Dan Leonard explores the challenges and opportunities in implementing value-based contracts.
Optimization of Medication Use at Accountable Care Organizations
This study assesses a broad range of factors related to how accountable care organizations optimize medication use and meet financial and quality metrics.
AMCP Partnership Forum on Value in Oncology Proceedings Published in JMCP
The Journal of Managed Care & Specialty Pharmacy this week published the proceedings from the Academy of Managed Care Pharmacy partnership forum, “Driving Value and Outcomes in Oncology,” which…
Incorporating What Matters to Patients in Quality Measures: A Discussion With NPAF’s Dr. Balch
NPC spoke with Alan Balch, PhD, chief executive officer of the National Patient Advocate Foundation, to ask his thoughts about the impact of quality measures on patient care, particularly in the…
How Can We Improve Oncology Quality Measurement in Accountable Care?
NPC and Discern Health analyzed the current oncology quality measure landscape for 10 high-priority cancers, published in the white paper "Improving Oncology Quality Measurement in Accountable Care,"…
When Is It Less Acceptable for Patients to Face Higher Cost-Sharing?
A new study explores when variation in consumer cost-sharing makes sense, and when it is less acceptable for patients with the same or similar conditions to have different out-of-pocket costs, as…